IBOGAINE Act
- Sponsor
- Rep. Luttrell, Morgan [R-TX-8]
- Committees
- Judiciary Committee (primary)
- Last action
- Jul 17, 2026
Bottom line
The IBOGAINE Act seeks to streamline regulatory pathways and foster research to make promising psychedelic therapies, especially ibogaine, more accessible for patients, including veterans, suffering from serious mental illnesses.
What it actually does
This bill aims to accelerate the development and access to psychedelic drugs, particularly ibogaine, for treating serious mental illness. It establishes a National Health Priority Voucher Pilot Program for FDA priority review, expands the federal Right to Try law to cover Schedule I controlled substances, revises DEA quota requirements for Schedule I and II drugs, and mandates expedited rescheduling consideration for ibogaine. The bill also enhances interagency collaboration and establishes new roles and reporting requirements within the Department of Veterans Affairs to support emerging therapeutic interventions for veterans.
Proponents argue
Supporters argue that this bill is a critical step to address the severe mental health crisis in the United States, particularly among veterans, by removing outdated regulatory barriers that hinder the development and access to potentially life-saving psychedelic treatments. They contend that the current system is too slow and that these reforms will accelerate innovation, reduce foreign dependency on drug supply chains, and provide new hope for those who have not responded to conventional therapies.
Opponents contend
Critics may raise concerns that expediting regulatory processes for Schedule I controlled substances could compromise patient safety by potentially bypassing rigorous clinical trial standards. They might also argue that loosening DEA controls could increase the risk of diversion and misuse of these substances, posing public health challenges. Some may also question the specific focus on ibogaine, suggesting it could create an uneven playing field for other promising compounds.
The bill is moderately complex due to its intricate changes to FDA and DEA regulatory frameworks, requiring careful reading to understand the interplay between different agencies and programs. An informed reader will need sufficient time to grasp its full implications.
Section 3
Definition of Ibogaine
This section amends the Controlled Substances Act to provide a specific definition for 'ibogaine.' It includes the plant Tabernanthe iboga and any similar compounds or analogs that act on neuroplasticity, opioid receptors, or serotonergic pathways. The purpose of these compounds, as defined, is to interrupt addiction cycles and restore neurological function disrupted by trauma, chronic substance use, or traumatic brain injury, while being distinct from existing breakthrough therapies.
Supporters argue
Supporters argue that providing a clear, statutory definition for ibogaine is essential to facilitate research and development into its therapeutic potential, especially given its unique mechanisms of action for serious mental health conditions.
Critics contend
No specific opposition is typically raised against defining a substance, but some may express concern that singling out a specific substance for definition could be seen as an implicit endorsement before full scientific consensus.
Tradeoffs
The tradeoff involves providing specific legal clarity to enable research versus the perception of prematurely favoring a particular compound over others without equivalent statutory definitions.
Section 4, adding new Section 524C to the FD&C Act
National Health Priority Voucher Pilot Program
This provision establishes a pilot program that awards non-transferable priority review vouchers to sponsors of 'national health priority products' upon their FDA approval. These products are broadly defined to include those addressing public health crises, breakthrough therapies, unmet medical needs, onshoring/supply chain resilience, affordability, or other critical health needs. The voucher entitles the holder to priority review for a single human drug application. The program is limited to one voucher per sponsor every 24 months and terminates on September 30, 2029. A user fee is established for using a voucher.
Section 5
Amendment to the Federal Right to Try Law
This section amends the existing federal Right to Try law to explicitly state that it supersedes any provisions of the Controlled Substances Act (CSA) that prohibit the unauthorized use, possession, distribution, dispensation, or transportation of an eligible investigational drug. This change clarifies the legal authority for terminally ill patients to access investigational Schedule I drugs under Right to Try, removing a previous legal ambiguity.
Section 6, adding new Section 303(p) to the CSA
DEA Special Registration for Schedule I Right to Try Drugs
This section mandates the Attorney General to establish a special registration process for physicians to directly administer eligible investigational Schedule I drugs to eligible patients under the Right to Try law. The process requires physicians to submit an application with evidence of existing controlled substance registration, compliance with Right to Try, manufacturer agreement for drug supply and guidance, state law compliance, and a description of storage/administration sites. The Attorney General must approve or issue a show-cause order within 45 days. It allows for electronic submissions, limits possession to specified amounts, and includes an expedited 30-day 'deemed approved' process for supplemental requests for additional drug amounts. A single registration can cover multiple sites within the same city/county under one institution.
Section 7, amending Section 306 of the CSA
Expedited Revision of DEA Production Quotas for Schedule I/II Drugs
This section amends the Controlled Substances Act to require the Attorney General to revise annual production quotas for Schedule I and II controlled substances within 90 days (Schedule I) or 60 days (Schedule II) if specific 'triggering events' occur. These events include a drug being transferred to another schedule, FDA approval/clearance, breakthrough therapy designation, investigational use exemption (IND), or approval for Phase 3 clinical trials. It also allows manufacturers to apply for expedited mid-year quota adjustments and mandates the Attorney General to establish annual sufficiency standards to meet legitimate medical, scientific, research, clinical, and industrial needs.
Section 10, amending Section 201 of the CSA
Expedited Rescheduling of Schedule I Drugs for Mental Health
This section requires the Attorney General, in consultation with the Secretary of Health and Human Services, to initiate and complete proceedings to determine whether to place a Schedule I drug in another schedule upon successful completion of Phase 3 clinical trials for a drug intended to treat a serious mental health disorder. These proceedings must be completed 'as quickly as practicable.' Furthermore, it specifically mandates the Attorney General, within 60 days of the bill's enactment, to take all necessary steps to determine whether to transfer ibogaine and ibogaine compounds from Schedule I to Schedule II.
Section 12
VA Reporting and Workforce Readiness for Emerging Therapies
This section requires the VA Under Secretary for Health to submit biannual reports to Congress on the Department's activities regarding emerging therapeutic interventions, including psychedelic-assisted therapies. These reports must cover research, clinical findings, veteran enrollment, interagency coordination, and recommendations for improving delivery and legislative/administrative actions. Additionally, it mandates the development of a workforce implementation-readiness plan, which includes assessing existing clinician training, developing standardized competency-based training frameworks, and implementing a plan for training and credentialing across VA medical centers to ensure widespread access.
The National Health Priority Review Voucher, unlike many existing priority review vouchers, is explicitly made non-transferable. The sponsor receiving the voucher cannot transfer the entitlement, except if the sponsor's ownership is transferred to a different entity.
Section 4(b)(2)
Why it matters:This is a critical detail that significantly alters the financial incentive structure of the voucher program. While not necessarily evasive, it's a departure from common practice for other FDA priority review vouchers, which are often sold for hundreds of millions of dollars, providing a major funding source for drug developers.
Case for: Proponents might argue that making the voucher non-transferable ensures that the direct benefit of expedited review remains with the company that developed the national health priority product, rather than becoming a purely financial asset to be traded. This could encourage long-term commitment to the priority area.
Case against: Critics would argue that non-transferability significantly reduces the financial value of the voucher, especially for smaller biotech companies that often rely on selling such vouchers to fund further research and development. This could diminish the overall incentive effect of the program, potentially favoring larger pharmaceutical companies with internal pipelines.
Estimated impact: Significantly alters the financial incentive for drug developers, potentially reducing the program's attractiveness to smaller entities that would otherwise monetize the voucher.
The Attorney General is required to approve or serve an order to show cause for a special registration application within 45 days. Furthermore, supplemental notifications for additional amounts of an eligible investigational drug are 'deemed approved' after 30 days unless the Attorney General serves an order to show cause.
Section 6(p)(3)(B) and (p)(5)(B)(ii)
Why it matters:These timelines are unusually aggressive for the DEA, an agency often criticized for slow administrative processes, especially concerning Schedule I substances. While not evasive, their significance lies in the challenge they pose to the agency's operational capacity and the potential for rapid, albeit controlled, expansion of access.
Case for: Proponents argue that these strict timelines are essential to ensure that terminally ill patients can access investigational treatments without undue delay, reflecting the urgency of their medical conditions. They push the DEA to operate with greater efficiency.
Case against: Critics may contend that such tight deadlines could strain the DEA's resources, potentially leading to less thorough reviews of applications and increased risk of diversion or administrative errors, especially given the sensitive nature of Schedule I substances.
Estimated impact: Significantly accelerates the administrative process for physicians to obtain and administer Schedule I investigational drugs under Right to Try, potentially challenging DEA's operational capacity.
The Attorney General is specifically mandated, within 60 days of the bill's enactment, to take all necessary steps to determine whether to transfer ibogaine and ibogaine compounds from Schedule I to Schedule II of the Controlled Substances Act.
Section 10(b)
Why it matters:While not technically 'buried' in the sense of being obscure, the direct, time-sensitive mandate for a specific substance (ibogaine) is a highly consequential action that stands out from the more general policy changes in the bill. It reflects a strong legislative intent regarding ibogaine's potential.
Case for: Proponents argue that this specific mandate is justified by the growing body of evidence supporting ibogaine's therapeutic potential, particularly for addiction and trauma, and the urgent need to remove its Schedule I classification to facilitate research and clinical use.
Case against: Critics might argue that singling out a specific substance for expedited rescheduling, rather than allowing it to proceed through the general process established in the same bill, could be seen as political interference in a scientific and regulatory determination, potentially setting a problematic precedent.
Estimated impact: Could lead to the reclassification of ibogaine from Schedule I to Schedule II within a very short timeframe, significantly altering its legal status for research and potential medical use.